Abstract
Aim:
To determine whether mycophenolate mofetil (MMF) has beneficial effects on refractory idiopathic thrombocytopenic purpura (ITP) and the corresponding cellular mechanism.
Methods:
Twenty refractory ITP patients resistant to corticosteroid and/or splenectomy and chemical therapy were given MMF 1.5-2.0 g/d orally for a 2 to 4-month period. Serum immunoglobulin was detected by rate nephelometry. Platelet-associated antibodies (PAIgG) were assayed by enzyme-linked immunosorbant assay. The immunophenotypic analysis was performed on a flow cytometer and cell apoptosis was detected with transferase mediated dUTP biotin nick end labeling (TUNEL) method.
Results:
Sixteen of the 20 (80%) patients had responses to MMF treatment; 9 (45%) achieved a complete response, 4 (20%) achieved a partial response, and 3 (15%) achieved a minor response. The therapeutic effects were found to be better in male patients than female patients. The number of CD3+ peripheral blood cells (PBCs) and CD4+ PBCs increased and the number of CD8+ PBCs decreased. The plasma level of IgG, IgM, IgA and platelet associated IgG (PAIgG) decreased in 86% of the patients. TUNEL assay showed that mycophenolate acid (MPA) 0.1 mmol/L induced apoptosis of peripheral blood mononuclear cells isolated from refractory ITP patients. The apoptosis rate was increased in male patients after treatment with MPA, but was unchanged in female patients.
Conclusion:
Therapy for a period of 8 to 16 weeks with mediandose of MMF was valuable for the treatment of refractory ITP.
Similar content being viewed by others
Article PDF
References
Cines DB, Blanchette VS . Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995–1008.
Bussel JB . Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 2002; 16: 31–6.
Becker BN . Mycophenolate mofetil. Transplant Proc 1999; 31: 2777–8.
Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41: 470–6.
Gellermann J, Querfeld U . Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004; 19: 101–4.
Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W . Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004; 19: 427–34.
Srinivas TR, Kaplan B, Meier-Kriesche HU . Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003; 4: 2325–45.
Cines DB, McKenzie SE, Siegel DL . Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25 Suppl 1: S52–6.
Narang M, Penner JA, Williams D . Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 2003; 74: 263–7.
Howard J, Hofferand AV, Prentice HG, Mehta A . Mycophenolate mofetil for the treatment of refractory auto immune haemolytic anemia and auto immune thrombocytopenia purpura. Br J Haematol 2002; 117: 712–5.
Kneitz C, Wilhelm M, Tony HP . Effective B cell depletion with rituximab in the treatment of autoimmune disease. Immunobiology 2002; 206: 519–27.
Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, et al. Mycophenolate mofetil for the treatment of steroid resistant idiopathic thrombocytopenic purpura. Eur J Hematol 2003; 70: 353–7.
Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA . Mycophenolate mofetil, an inhibitor of IMP dehydrogenase, causes paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004; 107: 63–8.
Cohn RG, Mirkovich A . Mycophenolic acid increases apoptosis lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411–8.
Padalko E, Verbeken E, Matthys P, Aerts JL, Clercq ED, Neyts J . Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol 2003; 3: 25–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by a grant from the Clinical key Programmer Foundation of the Ministry of public Health of China (No 20012131).
Rights and permissions
About this article
Cite this article
Zhang, Wg., Ji, L., Cao, Xm. et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin 26, 598–602 (2005). https://doi.org/10.1111/j.1745-7254.2005.00088.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00088.x
Keywords
This article is cited by
-
Efficacy and safety of mycophenolate mofetil in patients with immune thrombocytopenic purpura: a systematic review and meta-analysis
Clinical Rheumatology (2024)
-
Research progress of vapor phase corrosion inhibitors in marine environment
Environmental Science and Pollution Research (2022)
-
Autoimmunthrombozytopenie (AITP) des Erwachsenen: Klinik, Diagnose und Therapie
Wiener klinische Wochenschrift (2006)
-
Strategien zur Behandlung von Thrombozytopenien im Kindesalter
Monatsschrift Kinderheilkunde (2006)